Images List Premium Download Classic

Steoporosis

Steoporosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Gamma-diketones as wnt/beta -catenin signaling pathway activators
Samumed, Llc
September 14, 2017 - N°20170260176

The present disclosure provides γ-diketones or analogs thereof, that activate wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to ...
Composition for preventing, improving or treating postmenopausal osteoporosis comprising scopolin
Ajou University Industry-academic Cooperation Foundation
September 07, 2017 - N°20170252363

Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a ...
B- and y -diketones and y -hydroxyketones as wnt/ b -catenin signaling pathway activators
Ajou University Industry-academic Cooperation Foundation
August 31, 2017 - N°20170246154

Which activates wnt/β-catenin signaling and thus treats or prevents diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising parkinson's disease, strokes, ischemic cerebral disease, epilepsy, ...
Steoporosis Patent Pack
Download + patent application PDFs
Steoporosis Patent Applications
Download + Steoporosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steoporosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Composition and method of using mir-302 precursors as drugs for treating alzheimer's diseases
Mello Biotechnology, Inc.
August 03, 2017 - N°20170218362

This invention generally relates to a composition and method of using recombinant micrornas (mirna) and their hairpin-like precursors (pre-mirna) as therapeutic drugs for treating alzheimer's diseases (ad). More specifically, the present invention relates to the use of man-made mirna mir-302 precursors (pre-mir-302) for ad therapy in humans. These pre-mir-302 molecules can be mass produced in prokaryotes as a form of ...
N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4- hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and ...
Pimco 2664 Limited
August 03, 2017 - N°20170217881

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted n-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as hmc compounds) that are useful, for example, in the treatment of disorders (e. G., diseases) including, inflammation and/or joint destruction ...
Pharmaceutical formulations comprising chondroitin sulfate and hyaluronic acid derivatives
Fidia Farmaceutici S.p.a.
August 03, 2017 - N°20170216344

The present invention relates to pharmaceutical formulations containing a combination of specific high-molecular weight hyaluronic acid derivatives and chondroitin sulfate to be used in the treatment of osteoarthritis, of subchondral damage, osteoporosis, synovitis, tenosynovitis, tendinitis, tendinosis, as an intra-articular washing liquid and as a viscous substitute of synovial fluid following osteochondral surgery. These formulations are also suitable for the treatment ...
Steoporosis Patent Pack
Download + patent application PDFs
Steoporosis Patent Applications
Download + Steoporosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steoporosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treating androgen deprivation therapy induced hot flashes and bone loss in men using cis-clomiphene
Aspen Park Pharmaceuticals , Inc.
July 20, 2017 - N°20170202788

This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (bmd), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (bmd), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of ...
Polypeptides derived from calcitonin receptors and methods of use
The Research Foundation For The State University New York
July 06, 2017 - N°20170190760

The present invention is based, in part, on our discovery of compositions and methods that can be used to treat a patient who has a compromised bone (due, for example, to a disease such as osteoporosis or an injury such as a bone fracture). The compositions can also be administered prophylactically. For example, they can be administered to help maintain ...
Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4...
Pfizer Inc.
July 06, 2017 - N°20170190663

Novel salt forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid characterized by their x-ray powder diffraction pattern and solid-state nmr spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for ...
Solid oral formulation of fenretinide
Laurent Pharmaceuticals
July 06, 2017 - N°20170189356

Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited ...
Novel peptides for preventing or treating bone diseases and use thereof
Kyungpook National University Industry - Academic Cooperation Foundation
June 29, 2017 - N°20170183381

The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or ...
Llp2a-bisphosphonate conjugates for osteoporosis treatment
The Regents Of The University Of California
June 22, 2017 - N°20170174722

The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e. G. Llp2a, conjugated with a bisphosphonate drug, e. G. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal ...
Protease inhibitors
The Regents Of The University Of California
June 15, 2017 - N°20170166538

Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases:
Steoporosis Patent Pack
Download + patent application PDFs
Steoporosis Patent Applications
Download + Steoporosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steoporosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Crystalline forms and processes for the preparation of cannabinoid receptor modulators
Inflectis Bioscience
May 25, 2017 - N°20170144993

The present invention relates to crystalline forms of (1as,5as)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1h-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((s)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor and are therefore useful in the treatment of cb2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory ...
Triphenylethylene compounds and uses thereof
Inflectis Bioscience
May 25, 2017 - N°20170144975

Triphenylethylene compounds as dual aromatase inhibitors and selective estrogen receptors modulators are described. Also described are methods for treating patients of breast cancers, and patients of breast cancer comorbid with osteoporosis, using the described triphenylethylence compounds or pharmaceutical formulations thereof.
Calcitonin mimetics for treating diseases and disorders
Inflectis Bioscience
May 25, 2017 - N°20170143800

Calcitonin mimetic peptides having an amino acid sequence in accordance with seq id no:8 or seq id no:53, each of which may be carboxylated at its n-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its c-terminal, and in each of which the 1 and 7 position cysteine residues ...
Compositions and methods for the diagnosis and treatment of bone fractures and disorders
Universität Für Bodenkultur Wien
May 11, 2017 - N°20170130268

The present invention relates to the therapy, prophylaxis and diagnosis of disorders that are associated with aberrant bone mineral density, in particular osteoporosis; wherein the level of selected micro rnas in samples of patients are detected and wherein an increase or decrease of said level compared to the level of healthy individuals is indicative of the disorder.
Method for non surgical repair of vertebral compression fractures
Cedars-sinai Medical Center
May 04, 2017 - N°20170119823

Described herein are methods and compositions using pth and mesenchymal stem cells (mscs) for treatment of osteoporosis, bone fractures, and related conditions. Administration of both pth and mscs leads to increased homing of mscs to sites of vertebral bone and rib fracture. The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and ...
Calcium carbonate composition for ameliorating, preventing and treating osteoporosis, and manufacturing method therefor
Medience Co., Ltd.
May 04, 2017 - N°20170119815

The present invention relates to a calcium carbonate composition for ameliorating, preventing and treating osteoporosis, and a manufacturing method therefor. More specifically, the present invention relates to a calcium carbonate composition for alleviating, preventing and treating osteoporosis, the composition comprising calcium, magnesium and zinc, and having calcium carbonate microparticles formed by the supply of carbon dioxide gas. The present invention ...
Therapeutic agents for reducing parathyroid hormone levels
Kai Pharmaceuticals, Inc.
April 27, 2017 - N°20170114095

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, x1-x2-x3-x4-x5-x6-x7, wherein the x1 subunit comprises a thiol-containing moiety and the distribution of charge on the x2-x7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, ...
Urea compounds and their use as enzyme inhibitors
Kai Pharmaceuticals, Inc.
April 13, 2017 - N°20170101381

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, ...
Loading